Treatment of chronic cerebral insufficiency, including conditions after ischemic stroke and vascular dementia. Mitigation of mental and neurological symptoms of cerebral circulation failure. Treatment of chronic circulatory disorders in choroid and retina. Treatment of vascular disorders.
Composition:
1 tabl contains 5 mg or 10 mg of vinpocetine. The product contains latose.
Action:
Vinpocetine is a compound with a complex mechanism of action, positively influencing brain metabolism and blood flow in the brain, as well as the rheological properties of blood. It has a protective effect on the nervous tissue: it alleviates the detrimental effect of cytotoxic reactions caused by amino acids, intensifies the neuroprotective effect of adenosine. Vinpocetine stimulates brain metabolism: increases brain Glucose and oxygen consumption, increases brain cell tolerance to hypoxia, increases glucose transport across the blood-brain barrier, changes glucose metabolism to a more favorable energy pathway, selectively inhibits the cGMP-PDE phosphodiesterase-dependent isozyme Ca complex2+-calmodulin, as a result of which the concentration of cAMP and cGMP increases in the brain and relaxes the smooth muscle of the blood vessels. Vinpocetine increases ATP levels and ATP / AMP ratio in the brain, increases the metabolism of noradrenaline and serotonin in the brain, stimulates the noradrenergic system and has antioxidant effects. Vinpocetine improves brain microcirculation: it inhibits platelet aggregation, reduces pathologically increased blood viscosity, increases the ability to deform erythrocytes and inhibits the uptake of adenosine by erythrocytes, facilitates oxygen transport to the brain tissue by reducing the affinity of oxygen to erythrocytes. Selectively increases blood flow through cerebral vessels: increases the cerebral fraction of cardiac output, reduces the resistance of cerebral vessels without altering the systemic circulation parameters. Vinpocetine does not cause a stealth effect - it increases the perfusion of areas with impaired blood supply, without causing changes in places with proper blood flow. After oral administration, the drug is rapidly absorbed from the gastrointestinal tract. Cmax in plasma occurs after 1 hour after administration. Plasma protein binding is 66%. Total bioavailability is 7%. The clearance of vinpocetine is greater than the hepatic clearance, which indicates the extrahepatic metabolism of the drug. T0,5 It is about 5 hours. The drug is excreted in the urine (60%) and faeces (40%).
Contraindications:
Hypersensitivity to vinpocetine or auxiliary substances. acute haemorrhagic stroke. Severe ischemic heart disease. Severe heart rhythm disturbances. Pregnancy and breastfeeding. Children (insufficient data in this age group).
Precautions:
Patients with long QT syndrome and patients using drugs that cause QT prolongation are advised to perform ECG check-ups. The product contains lactose - should not be used in patients with rare hereditary galactose intolerance, Lapp lactase deficiency or malabsorption of glucose-galactose.
Pregnancy and lactation:
Use during pregnancy and breastfeeding is contraindicated.
Side effects:
Uncommon: sleep disorders (insomnia, drowsiness), headache and dizziness, weakness, ST segment depression, QT prolongation, tachycardia and additional heart contraction, changes in blood pressure (mainly lowering of blood pressure), headache, nausea, heartburn, dry mouth, increased liver enzymes, skin hypersensitivity reactions. Rare: abdominal pain, leukopenia.
Dosage:
Orally. Adults.Table. 5 mg: 1-2 tabl. Three times a day; maintenance dose: 1 tablet 3 times a day.Table. forte 10 mg: 1 tabl. 3 times a day. There is no need to change the dose in patients with liver or kidney disease. The tablets should be taken after a meal.